María Del Rocío Hernández-Morales, Jorge Manuel Ramírez-Sánchez, Eleazar Mancilla-Hernández, Norma Lara-Dávalos, Samara Nazarala-Sánchez, Margarita Aguirre-Barbosa
{"title":"住院患者药物不良事件:发生率、原因和危险因素。","authors":"María Del Rocío Hernández-Morales, Jorge Manuel Ramírez-Sánchez, Eleazar Mancilla-Hernández, Norma Lara-Dávalos, Samara Nazarala-Sánchez, Margarita Aguirre-Barbosa","doi":"10.29262/ram.v70i2.1117","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine prevalence, causes and risk factors of ADE in hospitalized patients of a General Hospital.</p><p><strong>Methods: </strong>Observational and analytical case-control study, carried out in patients hospitalized for adverse drug events, treated at the Hospital General Dr. Eduardo Vázquez N, in Puebla, Mexico, between, June 2019 to June 2021. For the statistical analysis, percentages, frequencies, means, odds ratio, χ2, and multiple binary logistic regression were used. Data were analyzed using the Statistical Package for the Social Sciences 23 program.</p><p><strong>Results: </strong>A total of 132 patients (66 cases and 66 controls) were registered. Of the group of cases, 26 patients treated for medication error and 40 with adverse drug reaction were reported. The prevalence of adverse drug events was 3.6%. The drugs and factors associated with the most reported adverse events were: antibiotics, anti-inflammatories; average age of 35 years (SD: 17.41); gender: 39.3% men, 60.7% women; services re-ported with the greatest attention: Emergencies and Surgery; frequent route of administration: intravenous (32.3%); main symptoms: skin; symptoms associated with adverse drug reactions: type A pruritus [OR: 8.5, p = 0.001(CI95%: 0.035-0.393)], type B pruritus [OR: 11, p = 0.001 (CI95%: 0.021-0.368)]; urticaria [OR: 19, p = 0.005(CI95%: 0.007-0.412)]. Risk factors associated with adverse events were: female gender [OR: 2.6, p = 0.05 (CI95%: 1.33-5.43)], history of allergy [OR: 3.4, p = 0.033 (CI95%: 1.04-8.40)] and prolonged hospital stay [OR: 5.4, p = 0.023 (CI95%: 3.82-6.74)].</p><p><strong>Conclusions: </strong>The majority of ADEs were EM or ADR type A, both preventable reactions, so patient safety should be a priority when prescribing.</p>","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"70 2","pages":"72-79"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Adverse drug events in hospitalized patients: prevalence, causes and risk factors].\",\"authors\":\"María Del Rocío Hernández-Morales, Jorge Manuel Ramírez-Sánchez, Eleazar Mancilla-Hernández, Norma Lara-Dávalos, Samara Nazarala-Sánchez, Margarita Aguirre-Barbosa\",\"doi\":\"10.29262/ram.v70i2.1117\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To determine prevalence, causes and risk factors of ADE in hospitalized patients of a General Hospital.</p><p><strong>Methods: </strong>Observational and analytical case-control study, carried out in patients hospitalized for adverse drug events, treated at the Hospital General Dr. Eduardo Vázquez N, in Puebla, Mexico, between, June 2019 to June 2021. For the statistical analysis, percentages, frequencies, means, odds ratio, χ2, and multiple binary logistic regression were used. Data were analyzed using the Statistical Package for the Social Sciences 23 program.</p><p><strong>Results: </strong>A total of 132 patients (66 cases and 66 controls) were registered. Of the group of cases, 26 patients treated for medication error and 40 with adverse drug reaction were reported. The prevalence of adverse drug events was 3.6%. The drugs and factors associated with the most reported adverse events were: antibiotics, anti-inflammatories; average age of 35 years (SD: 17.41); gender: 39.3% men, 60.7% women; services re-ported with the greatest attention: Emergencies and Surgery; frequent route of administration: intravenous (32.3%); main symptoms: skin; symptoms associated with adverse drug reactions: type A pruritus [OR: 8.5, p = 0.001(CI95%: 0.035-0.393)], type B pruritus [OR: 11, p = 0.001 (CI95%: 0.021-0.368)]; urticaria [OR: 19, p = 0.005(CI95%: 0.007-0.412)]. Risk factors associated with adverse events were: female gender [OR: 2.6, p = 0.05 (CI95%: 1.33-5.43)], history of allergy [OR: 3.4, p = 0.033 (CI95%: 1.04-8.40)] and prolonged hospital stay [OR: 5.4, p = 0.023 (CI95%: 3.82-6.74)].</p><p><strong>Conclusions: </strong>The majority of ADEs were EM or ADR type A, both preventable reactions, so patient safety should be a priority when prescribing.</p>\",\"PeriodicalId\":21175,\"journal\":{\"name\":\"Revista alergia Mexico\",\"volume\":\"70 2\",\"pages\":\"72-79\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista alergia Mexico\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29262/ram.v70i2.1117\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista alergia Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29262/ram.v70i2.1117","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的:了解某综合医院住院患者发生ADE的情况、原因及危险因素。方法:观察性和分析性病例对照研究,对2019年6月至2021年6月在墨西哥普埃布拉市Eduardo Vázquez N总医院治疗的因药物不良事件住院的患者进行研究。统计分析采用百分比、频率、均数、优势比、χ2和多元二元logistic回归。数据分析使用统计软件包为社会科学23程序。结果:共登记患者132例,其中66例为病例,66例为对照组。其中用药错误26例,不良反应40例。药物不良事件发生率为3.6%。与报告最多的不良事件相关的药物和因素是:抗生素、抗炎药;平均年龄35岁(SD: 17.41);性别:男性39.3%,女性60.7%;最受关注的服务报告:急诊和外科;常见给药途径:静脉注射(32.3%);主要症状:皮肤;与药物不良反应相关的症状:A型瘙痒[OR: 8.5, p = 0.001(CI95%: 0.035-0.393)], B型瘙痒[OR: 11, p = 0.001(CI95%: 0.021-0.368)];荨麻疹[OR: 19, p = 0.005(CI95%: 0.007-0.412)]。与不良事件相关的危险因素为:女性[OR: 2.6, p = 0.05 (CI95%: 1.33-5.43)]、过敏史[OR: 3.4, p = 0.033 (CI95%: 1.04-8.40)]、住院时间过长[OR: 5.4, p = 0.023 (CI95%: 3.82-6.74)]。结论:ade以EM或ADR A型为主,均为可预防的反应,在处方时应优先考虑患者安全。
[Adverse drug events in hospitalized patients: prevalence, causes and risk factors].
Objective: To determine prevalence, causes and risk factors of ADE in hospitalized patients of a General Hospital.
Methods: Observational and analytical case-control study, carried out in patients hospitalized for adverse drug events, treated at the Hospital General Dr. Eduardo Vázquez N, in Puebla, Mexico, between, June 2019 to June 2021. For the statistical analysis, percentages, frequencies, means, odds ratio, χ2, and multiple binary logistic regression were used. Data were analyzed using the Statistical Package for the Social Sciences 23 program.
Results: A total of 132 patients (66 cases and 66 controls) were registered. Of the group of cases, 26 patients treated for medication error and 40 with adverse drug reaction were reported. The prevalence of adverse drug events was 3.6%. The drugs and factors associated with the most reported adverse events were: antibiotics, anti-inflammatories; average age of 35 years (SD: 17.41); gender: 39.3% men, 60.7% women; services re-ported with the greatest attention: Emergencies and Surgery; frequent route of administration: intravenous (32.3%); main symptoms: skin; symptoms associated with adverse drug reactions: type A pruritus [OR: 8.5, p = 0.001(CI95%: 0.035-0.393)], type B pruritus [OR: 11, p = 0.001 (CI95%: 0.021-0.368)]; urticaria [OR: 19, p = 0.005(CI95%: 0.007-0.412)]. Risk factors associated with adverse events were: female gender [OR: 2.6, p = 0.05 (CI95%: 1.33-5.43)], history of allergy [OR: 3.4, p = 0.033 (CI95%: 1.04-8.40)] and prolonged hospital stay [OR: 5.4, p = 0.023 (CI95%: 3.82-6.74)].
Conclusions: The majority of ADEs were EM or ADR type A, both preventable reactions, so patient safety should be a priority when prescribing.